Quantum Biopharma (QNTM) Other Gross PP&E Adjustments (2019 - 2026)
Quantum Biopharma's (QNTM) quarterly Other Gross PP&E Adjustments came in at -$83048.0 in Q1 2026, down 137.81% year-on-year from $219645.7 in Q1 2025, and up 18.84% quarter-over-quarter from -$102320.0 in Q4 2025.
Quantum Biopharma (QNTM) Other Gross PP&E Adjustments (2019 - 2026) Analysis & Trends
Quantum Biopharma has disclosed Other Gross PP&E Adjustments across 7 years of filings, most recently posting -$83048.0 for Q1 2026.
- Other Gross PP&E Adjustments for Q1 2026 came in at -$83048.0, down 137.81% year-over-year; the trailing twelve-month figure through Mar 2026 was -$83048.0 (down 137.81% YoY), and the FY2025 annual result was -$102320.0, down 91.3% from the prior year.
- Other Gross PP&E Adjustments came in at -$83048.0 for Q1 2026 at Quantum Biopharma, up from -$102320.0 in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of -$8244.0 in Q2 2024 to a low of -$192422.0 in Q3 2022.
- The 5-year median for Other Gross PP&E Adjustments is -$102320.0 (2025), against an average of -$99679.5.
- Across the five-year window, Other Gross PP&E Adjustments jumped 89.94% in 2024 and plunged 1793.93% in 2025, its largest moves.
- Quantum Biopharma's Other Gross PP&E Adjustments stood at -$155196.0 in 2022, then jumped by 70.83% to -$45270.0 in 2023, then dropped by 18.15% to -$53488.0 in 2024, then sank by 91.3% to -$102320.0 in 2025, then increased by 18.84% to -$83048.0 in 2026.
- The last three Other Gross PP&E Adjustments figures came in at -$83048.0 (Q1 2026), -$102320.0 (Q4 2025), and -$121270.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -60,691.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -83,048.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -285.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -892,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -1.69 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -83,048.00 |
| Mar 31, 2026 | -83,048.00 |
| Dec 31, 2025 | -102,320.00 |
| Dec 31, 2025 | -102,320.00 |
| Sep 30, 2025 | -121,270.00 |
| Sep 30, 2025 | -121,270.00 |
| Jun 30, 2025 | -156,136.00 |
| Jun 30, 2025 | -156,136.00 |
| Mar 31, 2025 | -34,922.00 |
| Mar 31, 2025 | -34,922.00 |
| Dec 31, 2024 | -53,488.00 |
| Dec 31, 2024 | -53,488.00 |
| Sep 30, 2024 | -72,374.00 |
| Sep 30, 2024 | -72,374.00 |
| Jun 30, 2024 | -8,244.00 |
| Jun 30, 2024 | -8,244.00 |
| Sep 30, 2023 | -45,270.00 |
| Sep 30, 2023 | -45,270.00 |
| Jun 30, 2023 | -81,957.00 |
| Jun 30, 2023 | -81,957.00 |